The FDA approved today a once-daily pill form of semaglutide, the GLP-1 drug sold as Wegovy, for chronic weight management. In the trial that supported it, 307 adults took the pill or a placebo for 64 weeks; those on the drug lost on average 13.6% of body weight against 2.4% on placebo, and 16.6% versus 2.7% among those who stayed on treatment. The injectable version has already shown, in a 17,604-patient trial, fewer major cardiovascular events over about three years — 6.5% versus 8.0%. Nausea, vomiting and other gastrointestinal effects were common. The pill is expected in January, with pricing still to be announced. We write about this drug not to recommend it but because it is the clearest contrast available to the longevity industry's way of selling things.
What a real intervention looks like on paper. Randomized, placebo-controlled, in people, for more than a year, measuring an outcome that matters, with a separate trial for heart attacks and strokes, and with the harms counted in the same tables as the benefits. The weaknesses are on the record too: in an extension of an earlier trial, people who stopped the drug regained about two-thirds of the weight within a year, which means this is a chronic treatment, not a cure; the trial population was 307 people, not the millions who will take it; and long-term effects beyond a few years are still being learned. Compare that to the longevity aisle, where the typical product rests on a mouse, a biomarker, a twelve-week study and a testimonial, and no one counts the harms at all.
Loree’s takeFor a patient with obesity and its complications, this is medicine, and it has evidence I can show them along with the side effects and the regain data. For a patient at a healthy weight who wants it as a longevity hack — and I am asked — it is a drug with real risks, no evidence for that use, and a body that will want the weight back when they stop. The same molecule is a good decision for one person and a bad one for another. That is what evidence-based means, and it is why no label can make the decision for you.
Ben’s takeThis molecule is one of the most commercially successful drugs of the decade and it got there the slow way: trials, approvals, a cardiovascular study it did not have to run. The longevity industry sells the same promise — a longer, healthier life — with none of that, at comparable prices, and the gap in rigor is the whole story of this site. If you would not take a drug on the evidence behind the average longevity supplement, you have understood the point. Most people are taking the supplement.
Why it matters to a recovering optimizer. The pill's arrival will intensify a question we hear often: if a drug can do this, why bother with the fundamentals? Because the fundamentals are what the drug cannot replace — muscle kept through movement, sleep, food that is actually food, people at the table — and because the regain data tell you what happens when the pharmacology is all there is. The pill treats a disease. The fundamentals are how you live. Both can be true, and the second one is free.
Judge every longevity product by this pill's paperwork: randomized, in people, more than a year, harms counted. Almost none pass.
This post reports on evidence and expert disagreement. It is not medical advice; decisions about treatment belong with you and your clinician.